Laboratory evolution of Mycobacterium smegmatis in the presence of a fluoroquinolone leads to extreme drug resistance phenotype through the over-expression of Msmeg_5659-61 efflux pump.
Deepika RaiiD, Priyanka PadwaliD, Priyanka Purkayastha, Sarika MehraiD
Abstract
Resistance to multiple drugs is one of the significant barriers in the treatment of tuberculosis (TB). Knowledge of mechanisms of resistance is important to design effective treatment strategies. While mutations in genes coding for drug targets are thought to be the primary source of drug resistance, absence of mutations in these genes in many clinical strains suggests additional mechanisms of resistance. In this study, we employ adaptive laboratory evolution of Mycobacterium smegmatis to understand alternate mechanisms of drug resistance to norfloxacin, a fluoroquinolone (FQ). Results show that, in addition to fluoroquinolones, the evolved strain, Norr, is resistant to first-line drugs, rifampicin and isoniazid, and a second-line drug (amikacin), exhibiting extreme drug resistance phenotype. However, mutations were absent in any of the drug target genes. Drug uptake studies revealed that resistance is an attribute of decreased intracellular accumulation, primarily due to increased efflux. Further, drug transport kinetics demonstrate the involvement of efflux mediated resistance, which was found to be reversed in the presence of efflux pump inhibitors (EPIs). Gene transcript analysis suggests differential upregulation of multiple efflux pumps across the genome of the mutant. Overexpression of one of the upregulated efflux pumps Msmeg_5659-5661, partially explains the XDR phenotype of the mutant, while also suggesting that the contribution of other efflux pumps is significant. Whole-genome sequencing (WGS) of Norr reveals that a mutation in soxR, a transcriptional regulator, could be responsible for the upregulation of the Msmeg_5659-5661 efflux pump by direct regulation, and other efflux pumps via indirect regulation. Thus, the present work demonstrates that high resistance to multiple drugs can arise even when the Mycobacterium was subjected to a single selection pressure. Further, alterations in drug transport is an important mechanism that leads to resistance to multiple drugs simultaneously.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Efflux pump regulation and metabolic rewiring define the ceiling of efflux-mediated drug resistance in Mycobacteria
Shiksha Sharma, Sarika Mehra·bioRxiv·Jan 5, 2026
- Putative MFS transporter Rv1250 of Mycobacterium tuberculosis is involved in multidrug efflux activity
Debasmita Chatterjee, Ajit Ramesh Sawant, … Anindya Sundar Ghosh·bioRxiv·Aug 6, 2025
- Temporally variable drug profiles select for diverse adaptive pathways despite conservation of efflux-based resistance mechanism
- Rv0783c of Mycobacterium tuberculosis acts as a proton-motive force dependent multidrug efflux transporter involved in the efflux of structurally unrelated antibiotics and enhancing biofilm formation
Debleena Bhattacharyya, Debasmita Chatterjee, … Anindya Sundar Ghosh·Molecular MicrobiologyPeer-reviewed·Oct 30, 2026
- Efflux pump gene amplifications bypass necessity of multiple target mutations for resistance against dual-targeting antibiotic
K. P. T. Silva, G. Sundar, A. Khare·bioRxiv·Nov 30, 2022
- Selective pressure by rifampicin modulates mutation rates and evolutionary trajectories of mycobacterial genomes
E. Cebrian-Sastre, A. Chiner-Oms, … A. Castaneda-Garcia·bioRxiv·Feb 1, 2023